Patients with rheumatoid arthritis (RA)receiving filgotinib had meaningful improvements in patient-reported outcomes (PROs), including pain and fatigue, which occurred early and were maintained over time, according to a post hoc analysis presented at the 2024 European Congress of Rheumatology (EULAR).

“The quality of life of patients with RA can be severely impacted by pain, fatigue and impaired physical functioning that can vary week-on-week,” wrote a team of investigators led by Rieke Alten, MD, head of the Department of Internal Medicine, Rheumatology, Clinical Immunology, Osteology at Schlosspark-Klinik, University Medicine Berlin, Germany. “Filgotinib has previously demonstrated early onset of improvement in these meaningful PROs at the group level. However, it is unknown what proportion of patients improved and whether these improvements are sustained at the individual level.”

Source: MDMag

To view the third party content, kindly click on the link below or read more. You will then leave this site and enter a third party site.

https://www.hcplive.com/view/filgotinib-demonstrates-early-durable-pro-improvements-in-ra